
Impact of Copay Accumulator Legislation and IRA Changes to the Medicare Part D Benefit Design on Patient Affordability - On Demand
Recorded On: 02/21/2024
-
Register
- Prices available after logging in
As legislative changes reshape patient affordability and coverage, providers must stay informed to effectively support their patients. This session delves into the evolving landscape of copay accumulator adjustment programs, a pressing issue impacting commercial patient assistance. Additionally, we will explore the implications of the Inflation Reduction Act (IRA) on Medicare Part D, highlighting significant benefit design changes for 2024 and 2025. Gain actionable insights to address copay accumulator challenges, advocate for your commercial patients, and confidently guide your Medicare patients through the upcoming reforms.
Learning Objectives:
- Review how recent legislation is affecting copay accumulator adjustment policies and commercial patient affordability.
- Compare the Medicare Part D benefit designs across 2023, 2024, and 2025.
- Describe how future changes in the IRA will benefit the Part B and D patient.
The 2024 Operations Elevation series is supported through an unrestricted education grant by MHA and we thank them for their ongoing support.

Charles E Collins Jr., MS, MBA
President
Healthcare Stakeholder Solutions™ LLC
Healthcare Stakeholder Solutions is a managed markets consultancy in its 12th year focusing on healthcare delivery disparities. As president, Mr. Collins has over 34 years of career experience in the pharma industry. He has an extensive history of working across both multiple therapeutic areas and all managed market channels, helping to develop customized managed markets solutions. He serves on the Board of Directors as well as a Sr. Fellow to Medonomics, a nonprofit, nonpartisan think tank specializing in health policy, finance, and operations. He also serves as Treasurer and on the Board of Directors of the Specialty Pharmacy Certification Board. He has provided strategic managed markets consultation and tactical implementation to multiple major pharma clients.
In previous roles, he led the managed markets strategic counsel efforts providing insight and execution for commercial, Medicare, Medicaid, long-term care, retail pharmacy chains, and specialty pharmacy providers. Mr. Collins has over 25 years of managed markets expertise in account management, training, marketing, and developing effective pull-through initiatives. He currently speaks on a national basis regarding healthcare delivery disparities at AMCP, NASP, and ASEMBIA. Mr. Collins is a patient advocate and works with non-profit charitable organizations to raise awareness around healthcare trends that impact patient financial assistance programs. In addition, Mr. Collins has published supplements to the Journal of Clinical Outcomes Management® entitled Less is More…A Cost-Minimization Analysis of wilate® as an Effective Treatment Option for von Willebrand Disease and Assessing the Value Proposition of NUWIQ® in the Hemophilia A Market: An Illustrative Model in Cost Avoidance. Recently, Mr. Collins developed a whitepaper entitled “Payor Considerations When Evaluating a Specialty Pharmacy Partner for Rare Diseases and Limited Distribution Products”. Mr. Collins participated in the strategic launch of American Health & Drug Benefits® and, as a founding member of the editorial board, contributed actively for several years.
Mr. Collins graduated with a bachelor's degree in chemistry from Virginia Commonwealth University. Mr. Collins additionally holds a master's degree in clinical chemistry from Old Dominion University and a master's degree of business administration in pharmaceutical marketing from Saint Joseph's University in Philadelphia.
NHIA Requires planners, faculty, and others who affect the content of this activity to disclose all financial relationships they have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to policy.
Charles Collines reports the following financial disclosures:
- President of Healthcare Stakeholder Solutions
- Independent Contractor, Sanofi
Key:




